| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| The landscape of disease: mapping aplastic anemia |
|
Blood |
Aplastic Anemia |
| The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome |
|
BioDrugs |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The Problem of TP53-Mutant MDS/AML |
|
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The varieties of therapeutic experience: navigating treatment options for patients with PNH |
|
The Hematology, ASH Education Program |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
